Cassava Sciences (SAVA) shares are cratering by over 80% on Monday after the pharmaceutical company failed to meet its latest phase three trial goals on its Alzheimer's treatment drug, simufilam.

Yahoo Finance senior health reporter Anjalee Khemlani breaks down the story to Market Domination's Julie Hyman and Josh Lipton and what this all means for Cassava, especially as simufilam was its only drug in development at this time.

To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

This post was written by Luke Carberry Mogan.